Elsevier

JACC: Heart Failure

Volume 10, Issue 1, January 2022, Pages 12-23
JACC: Heart Failure

Clinical Research
Impact of Temporary Percutaneous Mechanical Circulatory Support Before Transplantation in the 2018 Heart Allocation System

https://doi.org/10.1016/j.jchf.2021.08.003Get rights and content
Under an Elsevier user license
open archive

Abstract

Objectives

This analysis sought to investigate the waitlist and post-transplant outcomes of individuals bridged to transplantation by using temporary percutaneous endovascular mechanical circulatory support (tMCS) through a status 2 designation (cardiogenic shock and exception).

Background

The 2018 donor heart allocation policy change granted a status 2 designation to patients supported with tMCS.

Methods

Adult patients in the United Network for Organ Sharing registry after October 18, 2018 who received a status 2 designation for tMCS were included and grouped by their status 2 criteria: cardiogenic shock with hemodynamic criteria (CS-HD), cardiogenic shock without hemodynamic criteria before tMCS (CS-woHD), and exception. Baseline characteristics, waitlist events (death and delisting), and post-transplant outcomes were compared.

Results

A total of 2,279 patients met inclusion criteria: 68.6% (n = 1,564) with CS-HD, 3.2% (n = 73) with CS-woHD, and 28.2% (n = 642) with exceptions. A total of 64.2% of patients underwent heart transplantation within 14 days of status 2 listing or upgrade, and 1.9% died or were delisted for worsening clinical condition. Among the 35.8% who did not undergo transplantation following 14 days, only 2.8% went on to receive a left ventricular assist device (LVAD). The 30-day transplantation likelihood was similar among groups: 80.1% for the CS-HD group vs 79.7% for the exception group vs 73.3% for the CS-woHD group; P = 0.31. However, patients who met criteria for CS-woHD had 2.3-fold greater risk of death or delisting (95% CI: 1.10-4.75; P = 0.03) compared with CS-HD patients after multivariable adjustment. Pre-tMCS hemodynamics were not associated with adverse waitlist events.

Conclusions

The use of tMCS is an efficient, safe, and effective strategy as a bridge to transplantation; however, patients with CS-woHD may represent a high-risk cohort. Transition to a durable LVAD was a rare event in this group.

Key Words

2018 allocation policy
heart transplant
mechanical circulatory support
outcomes
UNOS

Abbreviations and Acronyms

ECMO
extracorporeal membrane oxygenation
IABP
intra-aortic balloon pump
LVAD
left ventricular assist device
OPTN
Organ Procurement and Transplantation Network
PCWP
pulmonary capillary wedge pressure
pMCS
percutaneous endovascular mechanical circulatory support device
tMCS
temporary percutaneous endovascular mechanical circulatory support
UNOS
United Network for Organ Sharing

Cited by (0)

The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the Author Center.